(Total Views: 446)
Posted On: 04/15/2020 10:15:55 AM
Post# of 154147
Thanks.
A reasonable assumption is that the placebo patients will continue to deteriorate. Doesn't the decision to give lero violate the double-blind-ness of the trial?
I continue to hope that the FDA is able to lower their noses and see what's right in front of them and act without seeing the trials (at least for the critical cases) to the end and grant approval for unlimited EIND use.
A reasonable assumption is that the placebo patients will continue to deteriorate. Doesn't the decision to give lero violate the double-blind-ness of the trial?
I continue to hope that the FDA is able to lower their noses and see what's right in front of them and act without seeing the trials (at least for the critical cases) to the end and grant approval for unlimited EIND use.
(0)
(0)
